Almaarefa University
The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.

المخرجات

Research outputs

Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.

22 output Results for «Prostate»

ArticleClosed2025

Accelerating Prostate Cancer Detection Through Histopathological Image Analysis Using Artificial Intelligence

Microscopy Research and Technique · vol. 89 (5) · 687-704

Prostate cancer is a prevalent and serious health concern, ranking among the most frequently diagnosed cancers and a leading cause of cancer-related deaths in men worldwide. Early detection and accurate diagnosis are crucial for improving patient outcomes by limiting disease progression. Histopathological image analysis remains the gold standard for prostate cancer detection; however, manual interpretation is time-consuming and requires specialized expertise. To address these challenges, this study proposes a hybrid deep learning framework that combines an ensemble of transfer-learned CNNs (VGG-16, DenseNet-121, and AlexNet) with a fine-tuned Vision Transformer (ViT). The CNN ensemble extracts rich local features, while the ViT captures global contextual dependencies through a self-attention mechanism and a multilayer perceptron (MLP). Additionally, a cross-attention fusion (CAF) module integrates local and global features, and knowledge distillation (KD) enables a lightweight student network suitable for efficient clinical deployment. The study utilizes the publicly available PANDA dataset for training and testing. Preprocessing steps, including patch generation, gamma correction, and stain deconvolution, enhance image quality and feature representation. A comprehensive evaluation was conducted using standard performance metrics such as accuracy, true positive rate (TPR), true negative rate (TNR), precision, F1-score, false negative rate (FNR), and false positive rate (FPR). An ablation study confirmed the contribution of each module, highlighting the critical role of ensemble CNNs, CAF, and ViT in improving performance. Experimental results demonstrate that the proposed model outperforms conventional transfer learning models and existing state-of-the-art techniques, achieving 97.91% accuracy, along with significant improvements in TPR, TNR, and reduced FNR/FPR. The computational complexity, evaluated in terms of parameters, FLOPs, GPU memory, and inference time, indicates that the proposed model is more demanding than traditional CNNs. Nevertheless, the architecture strikes a practical balance between predictive accuracy and efficiency, making it suitable for real-world clinical applications. These findings underscore the potential of AI-powered hybrid models in expediting prostate cancer diagnosis and enabling timely intervention for improved patient outcomes.

prostate cancer detectionhistopathology image analysishybrid CNN-ViT modelcross-attention fusion
ArticleOpen access2025

Community Understanding and Attitudes Toward Prostate-Specific Antigen (PSA) Testing for Prostate Cancer Screening: A Cross-Sectional Survey Study From Saudi Arabia

Cureus · vol. 17 (11) · e97658-e97658

BACKGROUND: Prostate cancer (PC) significantly impacts men's health globally, including in Saudi Arabia. This study evaluates public awareness of prostate-specific antigen (PSA) testing, identifies barriers to screening participation, and explores factors influencing knowledge levels in Al Ahsa, Saudi Arabia. METHODS: A cross-sectional, self-administered electronic survey was conducted among 388 participants. Convenience sampling was utilized within a population of approximately 1.3 million. The Arabic questionnaire, adapted from a prior study, assessed demographic data, knowledge, and attitudes toward PC and PSA screening. Statistical analysis included descriptive statistics and chi-square or Fisher's exact tests, with significance set at p<0.05. RESULTS: Most respondents were aged 18-28 (75.3%, 292 participants), unmarried (71.6%, 278 participants), and possessed bachelor's degrees (48.7%, 189 participants). Although 62.4% (242 participants) recognized PC as the most common malignancy in men, only 29.1% (113 participants) were aware of PSA testing. A mere 5.9% (23 participants) had previously undergone PSA testing, despite 57.4% (223 participants) acknowledging age over 50 as a risk factor. Notably, 93.3% (362 participants) had never sought medical assistance for prostate issues, with 79.9% (310 participants) expressing the need for additional information. Employment status and educational attainment significantly influenced knowledge levels (p=0.004 and p=0.003). CONCLUSION: There is a substantial lack of knowledge and awareness about PC and PSA screening among Saudi participants. Barriers include low perceived risk and fear of diagnosis, compounded by reliance on informal sources such as social media. Addressing these gaps through targeted education and proactive outreach initiatives is crucial for enhancing awareness and encouraging early screening behaviors.

prostate cancerprostate-specific antigen testingprostate cancer screeningpublic awareness
ArticleOpen access2025

Acute generalized exanthematous pustulosis induced by iodinated contrast media: a case report

Dermatology Reports · vol. 17 (4)

Acute generalized exanthematous pustulosis (AGEP) is a rare pustular eruption commonly triggered by drugs. It is characterized by acute onset of pustules on erythematous-edematous skin and often presents with fever. This report describes AGEP following exposure to iodinated contrast media (ICM), specifically iobitridol, in a 68-year-old male with multiple comorbidities. The patient developed characteristic erythematous patches with pustules on the body after initial CT imaging with ICM for a prostate abscess. Histological findings and recurrence following re-exposure confirmed AGEP, which was attributed to ICM. This case emphasizes the need for awareness of ICM as a potential trigger for AGEP. Management included topical steroids and antihistamines, resulting in a rapid recovery.

acute generalized exanthematous pustulosisiodinated contrast mediaiobitridolcontrast media hypersensitivity
ArticleOpen access202411citation· Semantic Scholar

Novel coumarin-6-sulfonamide-chalcone hybrids as glutathione transferase P1-1 inhibitors

PLoS ONE · vol. 19 (8) · e0306124-e0306124

Multidrug resistance (MDR) mechanisms in cancer cells are greatly influenced by glutathione transferase P1-1 (hGSTP1-1). The use of synthetic or natural compounds as hGSTP1-1 inhibitors is considered an effective approach to overcome MDR. Nine compounds consisting of coumarin-6-sulfonamide linked to chalcone derivatives were synthesized and evaluated for their ability to inhibit hGSTP1-1. Among the synthetic derivatives, compounds 5g, 5f, and 5a displayed the most potent inhibitory effect, with IC50 values of 12.2 ± 0.5 μΜ, 12.7 ± 0.7 and 16.3 ± 0.6, respectively. Kinetic inhibition analysis of the most potent molecule, 5g, showed that it behaves as a mixed-type inhibitor of the target enzyme. An in vitro cytotoxicity assessment of 5a, 5f, and 5g against the human prostate cancer cell lines DU-145 and PC3, as well as the breast cancer cell line MCF-7, demonstrated that compound 5g exhibited the most pronounced cytotoxic effect on all tested cell lines. Molecular docking studies were performed to predict the structural and molecular determinants of 5g, 5f, and 5a binding to hGSTP1-1. In agreement with the experimental data, the results revealed that 5g exhibited the lowest docking score among the three studied inhibitors as a consequence of shape complementarity, governed by van der Waals, hydrogen bonds and a π-π stacking interaction. These findings suggest that coumarin-chalcone hybrids offer new perspectives for the development of safe and efficient natural product-based sensitizers that can target hGSTP1-1 for anticancer purposes.

glutathione S-transferase pichalcone derivativesmultidrug resistancemixed-type inhibition
ArticleOpen access2024

Efficacy of Next-Generation Sequencing in Identifying Genetic Markers for Prostate Cancer Risk

Journal of Pharmacy And Bioallied Sciences · vol. 16 (Suppl 4) · S3712-S3714

Background: Prostate cancer is one of the most prevalent cancers among men worldwide. The identification of genetic markers that contribute to the risk of prostate cancer can significantly enhance early diagnosis and personalized treatment strategies. Next-Generation Sequencing (NGS) has emerged as a powerful tool for uncovering genetic variations associated with various cancers, including prostate cancer. Materials and Methods: A cohort of 200 men, consisting 100 diagnosed with prostate cancer and 100 healthy controls, was recruited for this study. DNA samples were extracted from blood and tumor tissues, followed by library preparation and sequencing using an Illumina platform. Bioinformatic analysis was conducted to identify single nucleotide polymorphisms (SNPs), copy number variations (CNVs), and other genetic alterations linked to prostate cancer. Statistical analysis was performed to assess the association between identified genetic markers and prostate cancer risk. Results: < 0.001). Notably, the BRCA1, BRCA2, and HOXB13 genes exhibited significant variants in 20% of the prostate cancer patients. Furthermore, CNVs in the MYC and PTEN genes were observed in 15% and 10% of the patients, respectively. The control group displayed a significantly lower frequency of these genetic alterations, reinforcing their potential role as risk markers for prostate cancer. Conclusion: This study demonstrates the efficacy of NGS in identifying genetic markers associated with prostate cancer risk.

prostate cancergenetic risk markersnext-generation sequencingsingle nucleotide polymorphisms
ArticleOpen access202350citation· Semantic Scholar

Anticancer and apoptosis inducing potential of quercetin against a wide range of human malignancies

International Journal of Food Properties · vol. 26 (1) · 2590-2626

Quercetin, a flavonoid, is a dietary component that has attracted the attention of dietitians and medicinal chemists due to its anticancer potential. It is an antioxidant that has a significant role in reducing different human cancers such as breast, pancreatic, prostate, colon, blood, and oral. Being as an additional anti-cancer agent, it can stop cancer cell invasion and metastasis, induce apoptosis and autophagy, decrease cancer cell growth and proliferation. Multiple mechanisms, including suppression of pathways involved in cell survival, angiogenesis, and inflammation, are thought to be responsible for these anticancer effects. Quercetin has anti-inflammatory properties in both in vitro and in vivo tests, which is important as chronic inflammation is a major contributor to cancer. Preventing the synthesis of cytokines and chemokines that encourage inflammation can support to lessen inflammation and stop the spread of cancer. In cancer cells, quercetin can cause programmed cell death, which can stop the cells from rapidly multiplying and replicating. It provides protection against degradation of DNA induced by radiation and other carcinogens. The PI3K/Akt/mTOR pathway, the NF-κB system, and the Wnt/β-catenin pathway is few of the signaling pathways that quercetin modulates. It can activate the process of autophagy, which breaks the growth and range of cancer by having cells terminate and recover damaged or unwanted cellular mechanisms. The best treatment plans for various cancer kinds will need to be determined through additional research, which will also help confirm its safety and effectiveness in humans.

quercetinflavonoidsanticancer activityapoptosis
ArticleOpen access202335citation· Semantic Scholar

Chrysin a promising anticancer agent: recent perspectives

International Journal of Food Properties · vol. 26 (1) · 2294-2337

Honey, propolis, and passionflower contain a flavone known as chrysin. Researchers are studying chrysin to prove its potential to stop cancer cells growth. Chrysin cancer therapeutic potential is of great interest and numerous studies have been done to illustrate this potential. It is associated protein pathways effectively suppress tumor growth within the body. It is shown to have the ability to kill breast, prostate, lung, liver, and stomach cancerous cells. It can block Phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling in different animals against various cancers. Chrysin has the potential to kill breast cancer cells in a laboratory setting by inhibiting their cell division. Chrysin strongly suppresses Matrix metalloproteinase-9 (MMP-9), Urokinase plasminogen activator (uPA) and Vascular endothelial growth factor (VEGF), i.e. factors that can cause cancer. Chrysin has the ability to suppress the androgen receptor (AR), a protein necessary for prostate cancer development and metastasis. It starts the caspase cascade and blocks protein synthesis to kill lung cancer cells. Unnecessary apoptosis can be prevented by stopping certain protein pathways. Chrysin significantly decreased lung cancer metastasis in various animal-modeled studies. Chrysin induces apoptosis and stops colon cancer cells in the G2/M cell cycle phase. Chrysin suppresses colon cancer-promoting cyclin B1 and cyclin-dependent kinase 2. Chrysin suppressed cyclin B1 and CDK2 production in order to stop cancerous growth. Chrysin prevents tumor growth and cancer spread by blocking blood vessel expansion. Chrysin’s solubility, accessibility and bioavailability may limit its medical use. Chrysin targets numerous cancer-related communication pathways present in cells. Chrysin may reduce the chances of the onset of cancer, it can also serve as an alternative treatment as a whole to prevent and treat various cancers, but more clinical trials and research studies are needed to fully unlock its potential.

chrysinflavonesanticancer agentshoney
ArticleOpen access202334citation· Semantic Scholar

Anti-cancer perspectives of resveratrol: a comprehensive review

Food and Agricultural Immunology · vol. 34 (1)

Resveratrol (RVT) is well known for its chemo-preventive and therapeutic attributes against the various kinds of cancers such as breast, prostate, pancreatic, oral, brain, lung and liver. It has been found to inhibit glioblastoma cell growth, declining uPAR and its mediator ERK1/2, inhibiting the cell lines (EC-9706) growth and ADAM9 expression, up-regulating the lncRNAs and PPARγ, inhibition of MTA1 to modulate oncogenic miR-34a, miR-22 and miR-17, enhance the E-cadherin expression and decreased the expressions of Twist1 and vimentin, inhibiting ADAM9 expression, downregulation of ATP2A2 and ATP2A3 genes expressions in different breast cell lines, reduction in IL-6 and COX-2 expression, inhibition of Tax activity of LTR and HTLV-1 in SIRT1 deacetylase, suppression of epithelial-to-mesenchymal transition (EMT) and eEF1A expression and fracas interactions between TEAD and YAP and activation of Hippo/YAP signalling. Consequently, it can be suggested that RVT is a promising agent for treating aforementioned cancers due to its curing characteristics.

resveratrolanticancer activitychemopreventionbreast cancer
ArticleOpen access202324citation· Semantic Scholar

Curcumin: a bioactive compound with molecular targets for human malignancies

Food and Agricultural Immunology · vol. 34 (1)

Cancer is the second leading cause of death in the world and one of the major public health problems. Curcumin has anticancer activity including inducing apoptosis and inhibiting proliferation and invasion of tumours by suppressing a variety of cellular signalling pathways. It also possesses anti-tumour activity on different human cancers such as breast cancer, lung cancer, head and neck squamous cell carcinoma, prostate cancer, and brain tumours. In vitro and in vivo trails, curcumin inhibits tumour development and metastasis by inhibiting many pathways that regulate signalling in malignant cells, including Ras, p53, extracellular signal-regulated kinases (ERK), Wnt-protein kinase B (Akt), MAPKs, and PI3K. Curcumin can also inhibit IKK, EGFR, -catenin, cyclin D1, tumour necrosis factor (TNF), and anti-apoptotic genes such as Bcl-X and Bcl-2 along with downregulating nuclear transcription factors like NF-κB, which reduces the formation of pro-inflammatory cytokines like chemokines, TNF-, Interleukins and IL-1, IL-2, IL-6, IL-8, IL-12.Abbreviations: AP-1, activated protein 1; Bax, BCL-2-associated X protein; Bcl-XL, B-cell leukaemia extralarge; Cdc, cell division cycle; COX, cyclooxygenase; CY, cytochrome; DPPC, dipalmitoylphosphatidylcholine; EGFR, epidermal growth factor receptor; eIF, eukaryotic initiation factors; FOX, Forkhead box; FPTase, farnesyl protein transferase; HIF, hypoxia-inducible factor; histone deacetylase inhibitors, HLJ, DnaJ-like heat shock protein; Hsp, heat shock proteins; IL, interleukin; miRNA, micro ribonucleic acid; MMC, mitomycin-C; mTOR, mammalian target of rapamycin; NF-κB, nuclear transcription factor-kappa–B; PG, prostaglandins; PKB, protein kinase B; Ras, reticular activating system; TargOncol, human small cell lung cancer cell lines; TGF, transforming growth factor; TNF, tumour necrosis factor; TP, thymidine phosphorylase; TPA3, 12-O-tetradecanoylphorbol-13-acetate; u-PA, urokinase-type plasminogen activator; VEGF, vascular endothelial growth factors; XIAP, Xlinked inhibitor of apoptosis

curcuminanticancer activitymolecular targetsapoptosis
ArticleClosed20237citation· Semantic Scholar

A novel thieno[2,3‐d]pyrimidine derivative inhibiting vascular endothelial growth factor receptor‐2: A story of computer‐aided drug discovery

Drug Development Research · vol. 84 (6) · 1247-1265

Abstract Following the pharmacophoric features of vascular endothelial growth factor receptor 2 (VEGFR‐2) inhibitors, a novel thieno[2,3‐d]pyrimidine derivative has been designed and its activity against VEGFR‐2 has been demonstrated by molecular docking studies that showed an accurate binding mode and an excellent binding energy. Furthermore, the recorded binding was confirmed by a series of molecular dynamics simulation studies, which also revealed precise energetic, conformational, and dynamic changes. Additionally, molecular mechanics with generalized Born and surface area solvation and polymer‐induced liquid precursors studies were conducted and verified the results of the MD simulations. Next, in silico absorption, distribution, metabolism, excretion, and toxicity studies have also been conducted to examine the general drug‐like nature of the designed candidate. According to the previous results, the thieno[2,3‐d]pyrimidine derivative was synthesized. Fascinatingly, it inhibited VEGFR‐2 (IC50 = 68.13 nM) and demonstrated strong inhibitory activity toward human liver (HepG2), and prostate (PC3) cell lines with IC50 values of 6.60 and 11.25 µM, respectively. As well, it was safe and showed a high selectivity index against normal cell lines (WI‐38). Finally, the thieno[2,3‐d]pyrimidine derivative arrested the growth of the HepG2 cells at the G2/M phase inducing both early and late apoptosis. These results were further confirmed through the ability of the thieno[2,3‐d]pyrimidine derivative to induce significant changes in the apoptotic genes levels of caspase‐3, caspase‐9, Bcl‐2 associated X‐protein, and B‐cell lymphoma 2.

thieno[2,3-d]pyrimidine derivativesVEGFR-2 inhibitorsvascular endothelial growth factor receptor 2anticancer drug design
ArticleOpen access202257citation· Semantic Scholar

Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry · vol. 37 (1) · 573-591

Based on quinazoline, quinoxaline, and nitrobenzene scaffolds and on pharmacophoric features of VEGFR-2 inhibitors, 17 novel compounds were designed and synthesised. VEGFR-2 IC50 values ranged from 60.00 to 123.85 nM for the new derivatives compared to 54.00 nM for sorafenib. Compounds 15a, 15b, and 15d showed IC50 from 17.39 to 47.10 µM against human cancer cell lines; hepatocellular carcinoma (HepG2), prostate cancer (PC3), and breast cancer (MCF-7). Meanwhile, the first in terms of VEGFR-2 inhibition was compound 15d which came second with regard to antitumor assay with IC50 = 24.10, 40.90, and 33.40 µM against aforementioned cell lines, respectively. Furthermore, Compound 15d increased apoptosis rate of HepG2 from 1.20 to 12.46% as it significantly increased levels of Caspase-3, BAX, and P53 from 49.6274, 40.62, and 42.84 to 561.427, 395.04, and 415.027 pg/mL, respectively. Moreover, 15d showed IC50 of 253 and 381 nM against HER2 and FGFR, respectively.

VEGFR-2 inhibitorsanticancer agentsapoptosis inductionquinazoline derivatives
ArticleOpen access202228citation· Semantic Scholar

Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods

Genes · vol. 13 (4) · 655-655

Prostate cancer (PCa) is the most prevalent cancer (20%) in males and is accountable for a fifth (6.8%) cancer-related deaths in males globally. Smoking, obesity, race/ethnicity, diet, age, chemicals and radiation exposure, sexually transmitted diseases, etc. are among the most common risk factors for PCa. However, the basic change at the molecular level is the manifested confirmation of PCa. Thus, this study aims to evaluate the molecular signature for PCa in comparison to benign prostatic hyperplasia (BPH). Additionally, representation of differentially expressed genes (DEGs) are conducted with the help of some bioinformatics tools like DAVID, STRING, GEPIA, Cytoscape. The gene expression profile for the four data sets GSE55945, GSE104749, GSE46602, and GSE32571 was downloaded from NCBI, Gene Expression Omnibus (GEO). For the extracted DEGs, different types of analysis including functional and pathway enrichment analysis, protein–protein interaction (PPI) network construction, survival analysis and transcription factor (TF) prediction were conducted. We obtained 633 most significant upregulated genes and 1219 downregulated genes, and a sum total of 1852 DEGs were found from all four datasets after assessment. The key genes, including EGFR, MYC, VEGFA, and PTEN, are targeted by TF such as AR, Sp1, TP53, NF-KB1, STAT3, RELA. Moreover, miR-21-5p also found significantly associated with all the four key genes. Further, The Cancer Genome Atlas data (TCGA) independent database was used for validation of key genes EGFR, MYC, VEGFA, PTEN expression in prostate adenocarcinoma. All four key genes were found to be significantly correlated with overall survival in PCa. Therefore, the therapeutic target may be determined by the information of these key gene’s findings for the diagnosis, prognosis and treatment of PCa.

prostate cancerbenign prostatic hyperplasiadifferentially expressed geneskey genes
ArticleOpen access202225citation· Semantic Scholar

Design, Synthesis, Molecular Docking, and Biological Evaluation of Pyrazole Hybrid Chalcone Conjugates as Potential Anticancer Agents and Tubulin Polymerization Inhibitors

Pharmaceuticals · vol. 15 (3) · 280-280

Some (E)-3-(3-(4-(benzyloxy)phenyl)-1-phenyl-1H-pyrazol-4-yl)-1-phenylprop-2-en-1-one conjugates 5a–r were designed; synthesized; characterized by 1H, 13C NMR, and ESI-MS; and evaluated for tubulin polymerization inhibitory activity and in vitro cytotoxicity against breast (MCF-7), cervical (SiHa), and prostate (PC-3) cancer cell lines, as well as a normal cell line (HEK-293T). The compounds were also tested to determine their binding modes at the colchicine-binding site of tubulin protein (PDB ID-3E22), for in silico ADME prediction, for bioactivity study, and for PASS prediction studies. Among all the synthesized conjugates, compound 5o exhibited excellent cytotoxicity with an IC50 value of 2.13 ± 0.80 µM (MCF-7), 4.34 ± 0.98 µM (SiHa), and 4.46 ± 0.53 µM (PC-3) against cancer cell lines. The compound did not exhibit significant toxicity to the HEK cells. Results of the in silico prediction revealed that the majority of the conjugates possessed drug-like properties.

tubulin polymerization inhibitorsanticancer agentscolchicine binding siteMCF-7 cells
ArticleOpen access202216citation· Semantic Scholar

Origanum majorana L. Extract Attenuated Benign Prostatic Hyperplasia in Rat Model: Effect on Oxidative Stress, Apoptosis, and Proliferation

Antioxidants · vol. 11 (6) · 1149-1149

Benign prostatic hyperplasia (BPH) is a widespread androgenic illness influencing elderly men. It is distinguished by prostatic epithelial and stromal muscle cell proliferation. Inflammation, oxidative stress, and apoptosis have all been interrelated to the development of BPH. Marjoram (Origanum majorana L.) is a herb with reported antiproliferative, proapoptotic, and antioxidative properties, which have not yet been studied in relation to BPH. Consequently, in this work, an ethanolic extract of O. majorana was prepared in two doses (250 and 500 mg/kg/day) to be injected into castrated rats after induction of a testosterone-BPH model. Testosterone propionate (TP) was subcutaneously injected (0.5 mg/kg/day) for one week after castration to induce BPH. Forty adult Wistar male rats were randomly allocated into five groups: control, BPH model, high and low O. majorana doses (250, 500 mg/kg/day), and finasteride (FN) (0.8 mg/kg/day) as a positive control. Treatment was continued with drugs/normal saline for 28 days. Rat’s body and prostate were weighed, prostate index (PI) and % of prostate growth inhibition were calculated, serum dihydrotestosterone (DHT), prostatic content of superoxide dismutase (SOD), catalase (CAT), total antioxidant capacity (TAC), and malondialdehyde (MDA), DN damage, histopathological changes, immune expression of proliferating cell nuclear antigen (PCNA), caspase-3, α-SMA, and TGF-β1 were assessed. In addition, molecular quantitative PCR and ELISA analyses were performed to identify the expression of mRNAs and related proteins of both caspase-3 and TGF-β1 in prostate tissue from O. majorana-treated and untreated groups. Rats with BPH had significantly higher prostate weights and PI, higher DHT, DNA damage (8-hydroxyguanine, 8-OH-dG), and MDA levels with prominent PCNA, α-SMA, and TGF-β expression, but lower SOD, CAT, and TAC activity and caspase-3 expression. O. majorana (250 and 500 mg/kg/day)-treated groups revealed a decrease in prostate weights and PI, lower levels of DHT, suppressed oxidative stress, reduced tissue proliferation and fibrosis, and restored antioxidant and proapoptotic activity. Additionally, quantitative PCR and ELISA analysis showed that treatment with O. majorana significantly upregulated the expression of caspase-3 and downregulated the expression of TGF-β in prostate tissues of BPH rats. The data were confirmed by the immunohistological reactivity of these targeted markers in the prostate tissues. These effects were more significant with O. majorana 500 mg/mL/rat. In conclusion, the current study indicates the efficient use of O. majorana in the treatment of testosterone-induced BPH through its antiproliferative, proapoptotic, and antioxidative mechanisms.

benign prostatic hyperplasiaOriganum majoranaethanolic plant extractoxidative stress